Neuropsychiatric Symptoms in Behavioral Variant Frontotemporal Dementia and Alzheimer’s Disease: A 12-Month Follow-Up Study

Thais Bento Lima Da Silva¹,², Tiago Nascimento Ordonez²,³, Allan Gustavo Bregola⁴, Valéria Santoro Bahia¹, Mário Amore Cecchini¹,⁵, Henrique Cerqueira Guimarães⁶, Leandro Boson Gambogi⁶, Paulo Caramelli⁶, Marcio Luiz Figueiredo Balthazar⁷, Benito Pereira Damasceno⁸, Sonia Maria Dozzi Brucki¹, Leonardo Cruz de Souza⁹, Ricardo Nitrini¹ and Monica Sanches Yassuda¹,²*

¹Department of Neurology, Faculty of Medicine, University of São Paulo, São Paulo, Brazil, ²Gerontology, School of Arts, Sciences, and Humanities, University of São Paulo, São Paulo, Brazil, ³Graduate Program in Applied Statistics, University Center of United Metropolitan Colleges, São Paulo, Brazil, ⁴School of Health Sciences, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, United Kingdom, ⁵Human Cognitive Neuroscience, Psychology, University of Edinburgh, Edinburgh, United Kingdom, ⁶Neurology Division, University Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil, ⁷Neuroimaging Laboratory, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Brazil, ⁸Neurology Department, University of Campinas, Campinas, Brazil

Introduction: Neuropsychiatric symptoms in patients with frontotemporal dementia (FTD) are highly prevalent and may complicate clinical managements.

Objective: To test whether the Neuropsychiatry Inventory (NPI) could detect change in neuropsychiatric symptoms and caregiver’s distress in patients diagnosed with behavioral variant frontotemporal dementia (bvFTD) and Alzheimer’s disease (AD) from baseline to a 12-month follow-up and to investigate possible predictors of change in NPI scores.

Methods: The sample consisted of 31 patients diagnosed with bvFTD and 28 patients with AD and their caregivers. The Mini-Mental State Examination (MMSE), Addenbrooke’s Cognitive Examination Revised (ACE-R), the INECO Frontal Screening (IFS), the Frontal Assessment Battery (FAB), the Executive Interview (EXIT-25) and the NPI were applied. Descriptive statistics, Mann-Whitney U test, Wilcoxon test, Chi square ($\chi^2$) test and Linear Regression Analysis were used.

Results: NPI total and caregiver distress scores were statistically higher among bvFTD patients at both assessment points. MMSE, ACE-R scores significantly declined and NPI Total and Distress scores significantly increased in both groups. In the bvFTD group, age was the only independent predictor variable for the NPI total score at follow up. In the AD group, ACE-R and EXIT-25, conjunctively, were associated with the NPI total score at follow up.

Conclusions: In 12 months, cognition declined and neuropsychiatric symptoms increased in bvFTD and AD groups. In the AD group only, cognitive impairment was a significant predictor of change in neuropsychiatric symptoms.

Keywords: neuropsychiatric symptoms, behavioral dementia frontotemporal (bvFTD), Alzheimer’s disease (AD), elderly, aging
INTRODUCTION

Behavioral variant frontotemporal dementia (bvFTD) is a neurodegenerative syndrome which is usually diagnosed in midlife (mean age at onset around 58 years). Prevalence peaks in the early sixties, at about 13 cases per 100,000 individuals. Among the frontotemporal dementias, bvFTD is the most common one as it represents 50% of the cases (1).

The diagnosis of bvFTD is a challenging one, mainly in the initial stage of the disease, when its clinical expression is limited to personality and behavioral changes (2). Close inspection of behavioral changes could support accurate differential diagnosis from psychiatric diseases and other dementias (3).

In bvFTD, identifying neuropsychiatric symptoms and following them up over time is relevant for treatment and disease management, as they may relate to the progressive decline in social and emotional functions. The frequency and intensity of such symptoms may also help to distinguish bvFTD from other disorders. For instance, during bvFTD course, apathy can be the most frequent and intense symptom (2, 4).

In a previous study from our group (5), the most frequently reported symptoms among bvFTD patients were apathy (present in 85% of this patient group), irritability (65%), disinhibition (60%) and agitation/aggression (55%). Among patients with AD, depression (67%) and anxiety (63%) were most frequently reported. Those findings were in line with those from Riedijk et al. (6) and de Vugt et al. (7).

In a comparison between patients with bvFTD and Alzheimer’s disease (AD), Kumfor et al. (8) reported that 60% of AD patients and 84% of bvFTD patients had apathy, and it was more severe and frequent in bvFTD patients. Besides, bvFTD patients presented higher affective and cognitive apathy, while AD patients presented only higher cognitive apathy. Findings on affective apathy were related to changes in the ventral prefrontal cortex areas, behavioral apathy was related to the basal ganglia and cognitive apathy was related to changes in the dorsomedial prefrontal cortex. In addition, the authors pointed out that care burden is an expected outcome of affective and behavioral apathy in bvFTD patients (8).

Clinical studies with follow-up data regarding neuropsychiatric symptoms in bvFTD and possible predictors of change are lacking (9). Therefore, we investigated whether there was significant change in neuropsychiatric symptoms and caregivers’ distress in patients with bvFTD and AD, from baseline to the 12-month follow-up. We also investigated if there were associations between sociodemographic variables, cognitive performance and neuropsychiatric symptoms at both assessment points. This study is particularly important to describe clinical symptoms along the disease course in bvFTD and AD aiming to support treatment and disease management.

METHODS

Materials

Demographic Information

Questions about age, sex, and years of education were answered by the caregivers.

Cognitive Assessment

University-based neurology outpatient services databases were queried, and patients and their family caregivers were recruited for the study. Specialized dementia centers across three Brazilian universities were involved: the Cognitive and Behavioral Neurology Group (GNCC-SP) and the Program for the Elderly (PROTER) at the University of São Paulo; the Cognitive and Behavioral Neurology Group (GNCC-MG) at the Federal University of Minas Gerais and the Department of Neurology at the State University of Campinas (UNICAMP).

Participants

A total of 59 individuals, comprising 28 diagnosed with AD and 31 with bvFTD, were included in the study. Patients with bvFTD and with AD were matched for disease severity on the Clinical Dementia Rating scale–frontotemporal lobar degeneration [CDR-FTLD, (10, 11)], with scores from 0 to 3.

The diagnosis of bvFTD and AD was performed by neurologists, geriatricians and psychiatrists, based on clinical, neurological history, neuropsychological assessments and screening for reversible causes of dementia along with laboratory and neuroimaging exams: functional Magnetic Resonance Imaging (fMRI) and Fluorodeoxyglucose PET (FDG-PET patterns). Dementia was diagnosed based on the criteria from the Diagnostic and Statistical Manual 5th Edition [DSM-V, (12)]. International diagnostic criteria were employed for diagnosing probable bvFTD (13). The National Institute on Aging - Alzheimer’s Association (NIA/AA) criteria were used for AD diagnosis McKhann et al., (14).

Inclusion criteria for patients were age ≥ 40 years, education > 2 years and the presence of an informant who was involved in the daily routine of the patient (formal or informal carer; usually spending more than 8 h/day with the patient). Individuals presenting with visual, auditory or motor deficits preventing them from understanding instructions or performing cognitive tasks, individuals with other uncontrolled clinical diseases (such as hypertension and diabetes), serious and debilitating psychiatric disorders such as major depression, schizophrenia, bipolar disorder, clinical evidence or neuroimaging exam findings suggestive of vascular problems, dementias or etiologies other than bvFTD or AD, were excluded.

General cognition was assessed with the MMSE (0–30 points) [Folstein, (15)], (16) and the Addenbrooke’s Cognitive Examination-Revised (ACE-R) [Mioshi et al., (17)], (18) (0–100 points).

Executive functions were assessed with the INECO Frontal Screening (IFS) (0–30 points), the Frontal Assessment Battery (FAB) (0–18 points) and the Executive Interview (EXIT-25) (0–50 points). The IFS items assess: response inhibition and set shifting [motor programming, conflicting instructions, go-no go test, verbal inhibitory control (Modified Hayling test)], abstraction (proverb interpretation) and, working memory (backward digit span, verbal working memory and spatial working memory). The IFS generates a separate score for working memory which varies from 0 to 9 (19, 20). The FAB is comprised of six subtests...
which assess conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental mastery (21, 22). The EXIT-25 assesses verbal fluency, design fluency, anomalous sentence repetition, sensitivity to interference, among others (23, 24).

Neuropsychiatric Symptoms

The NPI assesses neuropsychiatric symptoms commonly found in dementia. It evaluates 12 domains (delusion, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/emotional lability, apathy, aberrant motor activity, night-time behavioral disturbances and appetite and eating abnormalities); thus yielding a composite symptom domain score (total score) (frequency × severity) ranging from 0 (absence of behavioral symptoms) to 144 points (maximum severity of behavioral symptoms) (25). The scale for assessing caregiver distress has scores ranging from 0 to 5 points (0 = no distress; 1 = minimal distress; 2 = mild distress; 3 = moderate distress; 4 = severe distress; and 5 = extreme distress) and the total distress score (NPI Distress) is calculated as the sum of the scores for each symptom.

Statistical Analyses

Initially, all quantitative variables (continuous and discrete) were analyzed using the Kolmogorov-Smirnov test to assess whether or not they followed a normal distribution. The absence of normal distribution was observed in most quantitative variables, so non-parametric tests were used: Chi-square (x²) test, Mann-Whitney U test and Wilcoxon test.

The Mann-Whitney U test was used, at different times, to compare bvFTD vs. AD groups. To analyze the differences between baseline and the 12-month follow up within the same clinical group, the Wilcoxon test was used. To analyze the influence of sociodemographic and cognitive variables on the NPI scores, linear regression analysis was used, with a multivariate model, and stepwise forward criteria for the selection of independent variables (age, gender, years of education, MMSE, ACER, EXIT-25, IFS, FAB), from the simplest to the most complex model (26).

The computer program Statistica 7.0 was used. The level of significance adopted for the statistical tests was 5%, that is, p-value < 0.05.

Procedures and Ethical Aspects

This study was approved by the Ethics Committee of the Hospital das Clínicas, protocol number 311.601. The study was conducted in compliance with international ethical standards, according to the Declaration of Helsinki.

RESULTS

The demographic and clinical characteristics of the patients are presented in Table 1. At baseline, 29 men (49.15%) and 30 women (50.85%) were included in the study. The mean age was 70.29 ± 9.85 years (range 50–87 years).

| Characteristics | bvFTD (n = 31) | AD (n = 28) | p-value |
|-----------------|---------------|-------------|---------|
| Women n (%)     | 13 (41.90%)   | 17 (60.71%) | 0.195a  |
| Age (range: 50–87) | 66.94 9.26  | 74.15 9.22 | 0.004b  |
| Schooling (0–21 Years) | 11.74 4.57  | 9.43 4.49  | 0.055b  |
| Clinical characteristics | | | |
| MMSE (Baseline) | 23.61 4.96  | 23.35 3.54  | 0.397b  |
| MMSE (1 Year)   | 22.50 4.69   | 22.87 3.91  | 0.775b  |
| ACER (Baseline) | 71.71 16.36  | 67.57 11.77 | 0.173b  |
| ACER (1 Year)   | 69.32 15.54  | 66.61 11.51 | 0.563b  |
| EXIT-25 (Baseline) | 14.96 9.36  | 12.43 7.82  | 0.358b  |
| EXIT-25 (1 Year) | 16.74 10.28 | 12.90 9.04  | 0.256b  |
| IFS (Baseline)  | 15.42 6.35   | 16.41 5.06  | 0.973b  |
| IFS (1 Year)    | 15.02 6.34   | 16.06 5.13  | 0.942b  |
| FAB (Baseline)  | 12.42 4.07   | 13.75 2.69  | 0.607b  |
| FAB (1 Year)    | 12.35 4.02   | 13.60 2.74  | 0.386b  |
| NPI Total (Baseline) | 45.58 23.85 | 25.64 16.92 | 0.001b  |
| NPI Total (1 Year) | 47.90 22.88 | 28.36 19.46 | 0.001b  |
| NPI Distress (Baseline) | 19.16 10.19 | 12.29 8.20 | 0.007b  |
| NPI Distress (1 Year) | 20.13 9.76  | 13.11 8.63 | 0.006b  |

aChi-square Test.  
bMann-Whitney U Test.  
cWilcoxon Matched Pairs Test.

Patients with AD were significantly older than the patients with bvFTD. MMSE and ACE-R scores decreased significantly from baseline to follow-up in both clinical groups. EXIT-25 scores significantly declined for the bvFTD group only, indicating that the executive dysfunction may have increased over time in this group. IFS and FAB scores remained unchanged for both groups (Table 1). NPI Total and Caregiver Distress scores were significantly higher for the bvFTD group at both assessment times. For both clinical groups, NPI Total and Distress scores significantly increased from baseline to follow up.

For a better graphical display of the NPI results, a radar chart was used (Figure 1). In this type of chart, the value axes start from a common center. For this study, the vertical main axis represents the 12 dimensions of the NPI. A line connects the score obtained in each assessment, forming a polygon. The scores obtained at baseline and at follow-up by different groups can be easily compared by looking at the area of the 12-sided polygon. The
larger the area of the polygon, the higher the reported symptoms. The shape of the polygon is also relevant, since asymmetries indicate that there are differences in the investigated domains.

When the clinical groups were compared at baseline, significant differences emerged, as higher scores can be seen for the bvFTD group for: agitation, eating disturbances and disinhibition (Figure 1; Table 2), the latter two were also observed in the NPI Distress subdomains (Table 3).

The groups were significantly different at baseline and follow-up, with higher scores for the bvFTD group, in NPI agitation, disinhibition, and eating disturbances, see Figure 1 and Table 2. For NPI hallucination and irritability significant differences between the groups emerged only at follow up. For the NPI distress, hallucinations, agitation and eating disturbances scores were significantly higher for the bvFTD group at follow up (Table 3).

We did not find significant correlations between NPI data and cognitive variables. However, using the Linear Regression Analysis, as seen in Tables 4, 5, age was the only independent predictor variable for the NPI Total score in the bvFTD Group in the follow up. And in the AD group, ACE-R and EXIT-25 (follow-up) were associated with the NPI Total score in the follow-up.

**DISCUSSION**

The aim of the present study was to test the hypothesis that there was significant change in neuropsychiatric symptoms, assessed by the NPI, in patients with bvFTD and AD, from baseline to the 12-month follow-up. We also investigated if there were changes in the NPI Caregiver Distress score and explored potential links between sociodemographic variables, cognitive performance and neuropsychiatric symptoms at baseline and follow-up. The groups were statistically similar in terms of sex, education, cognitive and functional assessment scores. The mean age was higher in the AD group. The clinical groups differed from the start in terms of NPI Total and Distress scores (bvFTD > AD).

In the present study, after 12 months, both groups presented with a reduction in MMSE and ACE-R scores and an increase in the NPI Total and Distress scores. An increase in executive dysfunction was also observed, according to the EXIT-25 scores, in the bvFTD group.

Neuropsychiatric symptoms (NPI Total and Distress scores) were statistically higher among bvFTD patients. Separately, agitation, disinhibition and eating disorders symptoms were higher in the bvFTD group, at baseline and follow-up assessments. Hallucination, agitation and irritability were higher in bvFTD at follow-up assessment in NPI Distress. These data confirm previous studies results (27, 28) as they indicate higher severity of NPI symptoms in bvFTD than in AD.

Not many studies have looked at differences between dementia subtypes in clinic-based samples using the NPI. In the first study that looked at differences in the NPI between AD and bvFTD, disinhibition, euphoria, apathy and aberrant motor behavior were found to be significantly higher in FTD (29). The same differences were noted in an Italian sample of patients with AD and FTD [Leroi et al., (30)]. Mendez et al. (31) had also observed higher scores for FTD patients in the verbal outbursts and inappropriate activity subscales of the BEHAVE-AD rating scale, while AD patients had higher scores on the affective disturbance and anxieties/phobias subscales.

In a recent study, with bvFTD, AD patients, and primary progressive aphasia (PPA) patients, Radakovic et al. (32) used the Dimensional Apathy Scale (DAS), which assesses: executive, emotional and initiation apathy. A total of 12 patients with PPA, 12 with bvFTD, and 28 with AD, and their caregivers (or relatives and close friends) answered the DAS and the apathy subtype awareness was obtained by the caregivers, to assess the discrepancy rate. There was higher emotional apathy and lower awareness for emotional apathy in bvFTD patients than in AD patients (32).

Liu et al. (28) suggested that neuropsychiatric symptoms are significant predictors of institutionalization (28). In bvFTD, patients’ caregivers seem to experience higher levels of burden.
and suffering than AD patients’ caregivers do. Neuropsychiatric symptoms seem to be associated with greater burden and suffering in bvFTD patients’ caregivers, as observed in the present study and previous ones (2, 5).

There is limited information regarding the trajectory of neuropsychiatric symptoms over time in AD and bvFTD. Present results suggest there was significant worsening in NPI (Total and Distress) in both groups. For some NPI domains, group differences reached significance at follow up, with worse scores in the bvFTD group, which suggests changes in NPI scores were of higher magnitude in this group. These results, in a short follow up period, suggest that it is relevant to track changes in neuropsychiatric symptoms over time, to better caregivers regarding care challenges. Higher emotional overload may be present in bvFTD patients’ caregivers, due to behavior and personality changes, as assessed with the NPI scale (5). Additionally, studies have reported the difficulty of caregivers of patients with bvFTD in managing day-to-day cognitive and behavioral impairments (33).

### TABLE 2 | Mean neuropsychiatric inventory scores reported by caregivers for each symptom.

| Characteristics       | bvFTD (n = 31) | AD (n = 28) | p-value |
|-----------------------|----------------|-------------|---------|
|                       | Mean  | SD   | Mean  | SD   |         |
| Delusions             | Baseline  | 0.84  | 2.45  | 0.11  | 0.57   | 0.192*  |
|                       | 1 year  | 0.97  | 2.51  | 0.14  | 0.76   | 0.108*  |
| Hallucinations        | Baseline  | 1.00  | 2.61  | 0.21  | 1.13   | 0.105*  |
|                       | 1 year  | 1.26  | 2.74  | 0.29  | 1.51   | 0.032*  |
| Agitation             | Baseline  | 6.03  | 4.61  | 3.21  | 4.55   | 0.031*  |
|                       | 1 year  | 6.61  | 4.43  | 3.32  | 4.72   | 0.009*  |
| Depression            | Baseline  | 2.90  | 3.62  | 2.18  | 3.57   | 0.245*  |
|                       | 1 year  | 3.29  | 3.87  | 2.00  | 3.33   | 0.119*  |
| Anxiety               | Baseline  | 4.32  | 4.17  | 4.00  | 4.32   | 0.693*  |
|                       | 1 year  | 4.58  | 4.07  | 3.68  | 4.27   | 0.356*  |
| Euphoria              | Baseline  | 2.81  | 3.99  | 1.21  | 2.50   | 0.148*  |
|                       | 1 year  | 2.58  | 3.82  | 1.54  | 2.89   | 0.322*  |
| Apathy                | Baseline  | 6.29  | 4.41  | 4.32  | 4.15   | 0.103*  |
|                       | 1 year  | 6.35  | 4.32  | 4.75  | 4.30   | 0.187*  |
| Disinhibition         | Baseline  | 5.13  | 4.54  | 2.18  | 3.75   | 0.005*  |
|                       | 1 year  | 5.16  | 4.56  | 3.04  | 4.10   | 0.044*  |
| Irritability          | Baseline  | 5.00  | 4.37  | 2.89  | 3.93   | 0.075*  |
|                       | 1 year  | 5.29  | 4.27  | 3.04  | 4.04   | 0.042*  |
| Aberrant motor behavior | Baseline  | 2.94  | 4.11  | 1.50  | 2.56   | 0.333*  |
|                       | 1 year  | 3.26  | 4.07  | 2.04  | 3.28   | 0.311*  |
| Sleep disturbances    | Baseline  | 2.77  | 3.66  | 1.29  | 3.03   | 0.066*  |
|                       | 1 year  | 2.84  | 3.66  | 1.93  | 3.70   | 0.230*  |
| Eating disturbances   | Baseline  | 5.45  | 4.20  | 2.46  | 3.49   | 0.007*  |
|                       | 1 year  | 5.71  | 3.97  | 2.75  | 3.92   | 0.005*  |

*aMann-Whitney U Test.
*bWilcoxon Matched Pairs Test.

### TABLE 3 | Mean neuropsychiatric inventory distress reported by caregivers for each domain.

| Characteristics       | bvFTD (n = 31) | AD (n = 28) | p-value |
|-----------------------|----------------|-------------|---------|
|                       | Mean  | SD   | Mean  | SD   |         |
| Delusions             | Baseline  | 0.35  | 0.98  | 0.07  | 0.38   | 0.209*  |
|                       | 1 year  | 0.42  | 1.03  | 0.14  | 0.76   | 0.121*  |
| Hallucinations        | Baseline  | 0.45  | 1.21  | 0.11  | 0.57   | 0.111*  |
|                       | 1 year  | 0.55  | 1.29  | 0.18  | 0.94   | 0.034*  |
| Agitation             | Baseline  | 2.55  | 1.80  | 1.54  | 2.03   | 0.074*  |
|                       | 1 year  | 2.81  | 1.70  | 1.50  | 1.99   | 0.018*  |
| Depression            | Baseline  | 1.58  | 1.73  | 1.00  | 1.52   | 0.188*  |
|                       | 1 year  | 1.68  | 1.72  | 0.89  | 1.47   | 0.069*  |
| Anxiety               | Baseline  | 1.84  | 1.61  | 1.61  | 1.64   | 0.620*  |
|                       | 1 year  | 2.06  | 1.59  | 1.50  | 1.64   | 0.205*  |
| Euphoria              | Baseline  | 1.06  | 1.55  | 0.75  | 1.38   | 0.380*  |
|                       | 1 year  | 0.94  | 1.46  | 0.82  | 1.39   | 0.730*  |
| Apathy                | Baseline  | 2.52  | 1.81  | 2.29  | 1.80   | 0.700*  |
|                       | 1 year  | 2.55  | 1.77  | 2.43  | 1.77   | 0.881*  |
| Disinhibition         | Baseline  | 2.16  | 1.92  | 1.18  | 1.87   | 0.023*  |
|                       | 1 year  | 2.19  | 1.96  | 1.61  | 2.02   | 0.172*  |
| Irritability          | Baseline  | 1.97  | 1.68  | 1.46  | 1.79   | 0.317*  |
|                       | 1 year  | 2.03  | 1.64  | 1.50  | 1.86   | 0.248*  |
| Aberrant motor behavior | Baseline  | 1.10  | 1.56  | 0.96  | 1.62   | 0.676*  |
|                       | 1 year  | 1.26  | 1.57  | 1.04  | 1.62   | 0.527*  |
| Sleep disturbances    | Baseline  | 1.29  | 1.70  | 0.54  | 1.20   | 0.062*  |
|                       | 1 year  | 1.32  | 1.76  | 0.82  | 1.49   | 0.248*  |
| Eating disturbances   | Baseline  | 2.23  | 1.65  | 0.75  | 1.29   | 0.001*  |
|                       | 1 year  | 2.29  | 1.60  | 0.82  | 1.42   | 0.001*  |

*aMann-Whitney U Test.
*bWilcoxon Matched Pairs Test.
Due to the epidemiological significance of bvFTD, further research studies on the clinical characterization of the disease course are needed. Research studies with larger samples, including different dementia subtypes, examining the links between cognitive performance, neuropsychiatric symptoms and caregiver burden are recommended.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethics Committee for Analysis of Research Projects (CAPPesq) of the Medical Board of the Clinics Hospital and of the University of São Paulo School of Medicine, protocol number 311.601. The study was conducted in compliance with international ethical standards (Declaration of Helsinki). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

This project was supported by the São Paulo Research Foundation (FAPESP) Grant Number: 11/04804-1 and 16/07967-2. Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Grant Number: 151684/2014-6 and by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Grant Number: 88881.131619/2016-01.

REFERENCES

1. Seeley WW. Behavioral variant frontotemporal dementia. Continuum. (2019) 25:1. doi: 10.1212/CON.0000000000000698
2. Benussi A, Premi E, Gazzina S, Brattini C, Bonomi E, Alberici A, et al. Progression of behavioral disturbances and neuropsychiatric symptoms in patients with genetic frontotemporal dementia. JAMA Network Open. (2021) 4:e2030194. doi: 10.1001/jamanetworkopen.2020.30194
3. Ranasinghe KG, Rankin KP, Lobach IV, Kramer JH, Sturm VE, Betchter BM. Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. Neurology. (2016) 86:600-10. doi: 10.1212/WNL.000000000002373
4. O’Connor CM, Clemson L, Hornberger M, Leyton CE, Hodges JR, Piguet O, et al. Longitudinal change in everyday function and behavioral symptoms in frontotemporal dementia. Neurol. Clin. Pract. (2016) 6:419-28. doi: 10.1212/CPJ.000000000000264
5. Lima-Silva TB, Bahia VS, Carvalho VA, Guimaraes HC, Caramelli P, Baltazar ML, et al. Neuropsychiatric symptoms, caregiver burden and distress in behavioral-variant frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord. (2015) 40:5-6. doi: 10.1159/000437351
6. Veltkin SF, De Vugt ME, Duivenvoorden HJ, Niermeijer MJ, Van Swieten JC, Verhey FR, et al. Caregiver burden, health-related quality of life and coping in dementia caregivers: a comparison of frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord. (2006) 22:405-12. doi: 10.1159/000095750
7. De Vugt ME, Riedijk SR, Aalten P, Tibben A, van Swieten JC, Verhey FR. Impact of behavioural problems on spousal caregivers: a comparison between Alzheimer’s disease and frontotemporal dementia. Dement Geriatr Cogn Disord. (2006) 22:35-41. doi: 10.1159/000093102
8. Kumpor F, Zhen A, Hodges JR, Piguet O, Irish M. Apathy in Alzheimer’s disease and frontotemporal dementia: distinct clinical profiles and neural correlates. Cortex. (2018) 103:350-9. doi: 10.1016/j.cortex.2018.03.019
9. Buoli M, Serati M, Caldiroli A, Galimberti D, Scarpini E, Altamura AC. Pharmacological management of psychiatric symptoms in frontotemporal dementia: a systematic review. J Geriatr Psychiatry Neurol. (2017) 30:3. doi: 10.1177/0891987717700506
10. Knopman DS, Kramer JH, Boeve BF, Caselli RJ, Graff-Radford NR, Mendez MF, et al. Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain. (2008) 131:2957-68. doi: 10.1093/brain/awn234
11. Knopman DS, Weintraub S, Pankratz VS. Language and behavior domains enhance the value of the clinical dementia rating scale. *Alzheimer's Dement.* (2011) 7:293–9. doi: 10.1016/j.jalz.2010.12.006
12. Sorrell JM. Diagnostic and Statistical Manual of Mental Disorders-5: implications for older adults and their families. *J Psychosoc Nurs Ment Health Serv.* (2013) 51:19–22. doi: 10.3908/02793695-20130207-01
13. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain.* (2011) 134:2456–77. doi: 10.1093/brain/awr179
14. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CJ Jr, Kawash MA, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* (2011) 7:263–269. doi: 10.1016/j.jalz.2011.03.005
15. Folstein FE, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res.* (1975) 12:189–198. doi: 10.1016/0022-3956(75)90026-6
16. Carvalho VA, Barbosa MT, Caramelli P.Brazilian version of the addenbrooke cognitive examination-revised in the diagnosis of mild Alzheimer disease. *Cogn Behav Neurol.* (2010) 23:8–13. doi: 10.1097/WNN.0b013e3181e52e5
17. Torralva T, Roca M, Gleichgerrcht E. INECO Frontal Screening (IFS): a brief, sensitive, and specific tool to assess executive functions in dementia. *Correct Version J.* (2009) 15:777–86. doi: 10.1011/S1355617709990145
18. Bahia VS, Cecchini MA, Cassimiro L, Viana R, Lima-Silva TB, et al. The accuracy of INECO frontal screening in the diagnosis of executive dysfunction in frontotemporal dementia and Alzheimer disease. *Alzheimer Dis Assoc Disord.* (2018) 32:314–9. doi: 10.1097/WAD.0000000000000255
19. Dubois B, Sachdevsky A, Litvan I, Pillon B. The FAB A frontal assessment battery at bedside. *Neurology.* (2000) 55:1621–6. doi: 10.1227/WNL.55.11.1621
20. Beato R, Amaral-Carvalho V, Guimarães HC, Tumas V, Souza CP, Oliveira GN, et al. Frontal assessment battery in a Brazilian sample of healthy controls: normative data. *Arq Neuropsiquiatr.* (2012) 70:278–80. doi: 10.1590/S0004-282X2012005000009
21. Royall DR, Mahurin RK, Gray KY. Beside assessment of executive impairment: the Executive Interview (EXIT). *J Amer Geriat Soc.* (1992) 40:1221–6. doi: 10.1111/j.1532-5415.1992.tb03646.x
22. Mattioni MNPS, Caramelli P. Limitations in the differential diagnosis between vascular dementia and Alzheimer disease based on brief cognitive testing. *Arq de NeuroPsiquiatr.* (2010) 68:185–8. doi: 10.1590/S0004-282X2010000200006
23. Camozzato AL, Kochhann R, Simeoni C, Konrath CA, Franz AP, Carvalho A, et al. Reliability of the Brazilian Portuguese version of the Neuropsychiatric Inventory (NPI) for Alzheimer’s disease patients and their caregivers. *Int Psychogeriatr.* (2008) 20:383–93. doi: 10.1017/S1041610207006254
24. Hair JR, Tatham RL, Anderson RE, Black W. *Multivariate Data Analysis.* 6th ed. NJ: Pearson Education (2005). 928p.
25. Devvenney E, Bartley L, Hoon C, O’Callaghan C, Kumnor F, Hornberger M, et al. Progression in behavioral variant frontotemporal dementia: a longitudinal study. *JAMA Neurology.* (2015) 72:12. doi: 10.1001/jamaneurol.2015.2061
26. Liu S, Liu J, Wang XD, Shi Z, Zhou Y, Li J, et al. Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer’s disease. *Int Psychogeriatr.* (2018) 30:8. doi: 10.1017/S1041610217002630
27. Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer’s disease. *Am J Psychiatry.* (1996) 153:1438–43. doi: 10.1176/ajp.153.11.1438
28. Leroy M, Bertoux M, Skrobala E, Mode E, Adnet-Bonte C, Le Ber I, et al. Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network. *Alzheimers Res Ther.* (2021) 13:1–11. doi: 10.1186/s13195-020-00753-9
29. Mendez MF, Perryman KM, Miller BL, Cummings JL. Behavioral differences between frontotemporal dementia and Alzheimer’s disease: a comparison on the BEHAVE-AD rating scale. *Int Psychogeriatr.* (1998) 10:155–62. doi: 10.1017/S1041610298006526
30. Radakovic R, Colville S, Cranley D, Starr JM, Pal S, Abrahams S. Multidimensional apathy in behavioral variant frontotemporal dementia, primary progressive aphasia, and Alzheimer disease. *J Geriatr Psychiatry Neurol.* (2020) 34:349–56. doi: 10.1177/0891988720924716
31. Otero MC, Levenson RW. Lower visual avoidance in dementia patients is associated with greater psychological distress in caregivers. *Dement Geriatr Cogn Disord.* (2017) 43:5–6. doi: 10.1159/000468146

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Da Silva, Ordonez, Bregola, Bahia, Cecchini, Guimarães, Gambogi, Caramelli, Ballhazar, Damasceno, Brucks, de Souza, Nitrini and Yassuda. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.